Quarterly report pursuant to Section 13 or 15(d)

Intangibles, net (Tables)

v3.21.2
Intangibles, net (Tables)
6 Months Ended
Jun. 30, 2021
Intangibles, net  
Schedule of JMC Intangible Asset

The table below provides a summary of the Journey intangible assets as of June 30, 2021 and December 31, 2020, respectively:

Estimated Useful

($ in thousands)

    

Lives (Years)

    

June 30, 2021

    

December 31, 2020

(Unaudited)

Total intangible assets – asset purchases

3 to 7

$

19,003

$

18,606

Accumulated amortization

 

  

 

(5,302)

 

(3,977)

Net intangible assets

 

  

$

13,701

$

14,629

Schedule of JMC recognized expense related to its product licenses

The table below provides a summary for the six months ended June 30, 2021, of Journey’s recognized expense related to its product licenses, which was recorded in costs of goods sold on the condensed consolidated statement of operations:

Intangible

($ in thousands)

    

Assets, Net

Beginning balance at January 1, 2021

$

14,629

Additions:

Exelderm milestone

397

Amortization expense

 

(1,325)

Ending balance at June 30, 2021

$

13,701

Schedule of future amortization of intangible assets

The future amortization of these intangible assets is as follows:

Total

($ in thousands)

    

Ximino®

    

Exelderm®

    

Accutane®

    

Amortization

Six months ending December 31, 2021

$

509

$

167

$

473

$

1,149

Year ended December 31, 2022

 

1,019

 

 

946

 

1,965

Year ended December 31, 2023

1,019

945

1,964

Year ended December 31, 2024

1,019

946

1,965

Year ended December 31, 2025

 

1,019

 

 

945

 

1,964

Thereafter

595

157

752

Sub-total

$

5,180

$

167

$

4,412

$

9,759

Assets not yet placed in service:

Anti-itch product license acquisition (amortization commencing second half of 2021)

3,942

Total

$

5,180

$

167

$

4,412

$

13,701